Browse: Departments Dates Agencies
Docket ID: [Docket No. 2003N-0573]
SUBJECT CATEGORY: Draft Animal Cloning Risk Assessment; Proposed Risk Management Plan; Draft Guidance for Industry; Availability
DOCUMENT SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of, and is requesting comment on, a draft risk assessment
on animal cloning. FDA's Center for Veterinary Medicine (CVM) developed
this draft risk assessment to evaluate the health risks to animals
involved in the process of cloning and to evaluate the food consumption
risks that may result from edible products derived from animal clones
or their progeny. FDA is also announcing the availability of, and is
requesting comment on, a proposed risk management plan for animal
clones and their progeny. The proposed risk management plan takes into
account the risks identified in the draft risk assessment and sets out
proposed measures that FDA might use to manage those risks. In
addition, FDA is announcing availability of draft guidance for industry
SUMMARY: Animal cloning risk assessment plan; industry guidance,
In July 2001, FDA's CVM issued an update on livestock cloning
(available at http://www.fda.gov/cvm/CVM_Updates/clones.htm) and
indicated its intention to work with stakeholders to assess potential
risks presented by cloning foodproducing animals. It also requested
that companies voluntarily refrain from introducing animal clones,
their progeny, or their food products (such as milk or meat) into the
human or animal food supply, pending completion of the risk assessment
process. The public participation phase of this process begins with the
release of draft documents entitled ``Animal Cloning: A Draft Risk
Assessment,'' ``Animal Cloning: Proposed Risk Management Plan for
Clones and Their Progeny,'' and ``Draft Guidance for Industry
Among the goals of our draft risk assessment were the determination of whether somatic cell nuclear transfer (SCNT), the process used to produce the clones being considered in the risk assessment, poses any unique risks to animals involved in cloning relative to other assisted reproductive technologies, and whether foods derived from animal clones or their progeny pose consumption risks greater than those posed by foods derived from their conventional counterparts. It specifically does not consider risk issues that may be posed by genetically engineered animals.
The draft risk assessment has been peer reviewed in accordance with the Office of Management and Budget's Information Quality Peer Review Bulletin. The peer reviewers' comments and the agency's response to them are posted on the Internet with the draft risk assessment (see the Electronic Access section of this document).
The proposed risk management plan describes proposed measures that the agency might use to address animal health and food consumption risks identified in the draft risk assessment that are within the agency's purview. It also describes the agency's plans with regard to issues that are not within the agency's authority to manage (e.g., ethics) regarding animal cloning.
The draft guidance for industry describes FDA's recommendations regarding the introduction of edible products from animal clones and their progeny into the food and feed supply. FDA will consider information received during the comment period in its preparation of a final risk assessment. To that end, FDA requests that any producers or breeders of clones who have additional data on the health of the clones or their progeny or composition of food products (i.e., meat or milk) derived from clones or their progeny share those data with us. Additionally, the agency reiterates that the release of these draft documents does not affect its request to industry to continue to refrain from introducing food products from clones and their progeny into the marketplace.
The draft guidance for industry is a level 1 draft guidance that is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance represents the agency's current thinking on the topic. The draft guidance document does not create or confer any rights for or on any person and will not operate to bind FDA or the public. Alternative methods may be used as long as they satisfy the requirements of the applicable statutes and regulations. III. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding the draft risk
assessment document, the proposed risk management plan, and the draft
guidance for industry. For convenience in reviewing the comments, FDA
requests that comments be separately identified as to which document
they address. Submit a single copy of electronic comments or two paper
copies of any mailed comments, except that individuals may submit one
paper copy. Comments are to be identified with the docket number found in brackets in the heading of this
[[Page 137]]
document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday. IV. Electronic Access
Persons with access to the Internet may obtain the documents at
http://www.fda.gov/cvm/cloning.htm. In an effort to better ensure broad
awareness of this Federal Register notice, FDA will announce it and
make copies available through the FDA Dockets Listserv (http://www.fda.gov/ohrms/dockets/FDAMAIL/DMBemaillist.htm ). To be added to any
of FDA's free email subscription services go to http://www.fda.gov.
Click on ``Subscribe to FDA's Email Lists,'' then follow the instructions provided.
Dated: August 18, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 069927 Filed 122806; 11:00 am]
BILLING CODE 416001S
FOR FURTHER INFORMATION CONTACT Larisa Rudenko, Center for Veterinary Medicine (HFV100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 2404536842, email: clones@cvm.fda.gov.
14 CFR Part 39 40 CFR Part 52 14 CFR Part 71 33 CFR Part 165 50 CFR Part 679 47 CFR Part 73 26 CFR Part 1 40 CFR Part 180 33 CFR Part 117 50 CFR Part 17 44 CFR Part 67 50 CFR Part 648 14 CFR Part 97 33 CFR Part 100 40 CFR Part 63 50 CFR Part 622 44 CFR Part 65 50 CFR Part 660 26 CFR Part 301 39 CFR Part 111 40 CFR Part 300 6 CFR Part 5 40 CFR Part 271 47 CFR Part 64 40 CFR Parts 52 and 81 50 CFR Part 665 44 CFR Part 64 10 CFR Part 50 49 CFR Part 571 47 CFR Part 76